The resignation of Prudential Financial's Japan life insurance CEO following a widespread employee misconduct scandal has triggered governance reviews and shaken investor confidence in one of the insurer's key international markets.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Champion Iron reports steady Q3 operational performance with improved costs and significant progress on its high-grade DRPF project. The company also details the fully-financed plan to acquire Norway's Rana Gruber, aiming to strengthen its foothold in the European steelmaking market.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
As the STOXX Europe 600 grapples with volatility, some investors are turning their gaze to smaller, often overlooked companies. We examine three European penny stocks, each with a market capitalization exceeding €10 million, assessing their potential amidst a challenging macroeconomic backdrop.
Despite a challenging price environment, Murphy Oil (MUR) reported strong operational execution for 2025 and laid out a capital plan focused on funding key international and offshore projects. While near-term production is set to dip, CEO Eric Hambly highlighted a transformative discovery in Vietnam and strategic portfolio expansion as pillars for future growth.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Dolby Laboratories (DLB) reported first-quarter results that exceeded analyst forecasts, prompting the company to raise its full-year guidance. The audio-visual technology leader cited earlier-than-anticipated deal closures, momentum in mobile and broadcast, and strategic wins with partners like Sony, TCL, and Peacock as key drivers.
An international tribunal has ruled against Shell and partner Eni in a cost-recovery dispute at Kazakhstan's Karachaganak field, potentially exposing the energy giants to a multi-billion dollar payout and forcing contract renegotiations that could reshape future cash flows from the strategic asset.
Lazard Ltd. reported strong fourth-quarter and full-year 2025 results, driven by record financial advisory fees and a rebound in assets under management. Executives framed the performance as validation of the firm's long-term 'Lazard 2030' strategy, highlighting talent investments and a robust pipeline for future growth.
A disappointing full-year EBITDA performance from its crucial Macau operations triggered a sharp sell-off in Las Vegas Sands stock, underscoring the lingering challenges facing the gaming giant in the wake of China's regulatory crackdown.
After a stellar multi-year run, Airbus shares have retreated recently, prompting investors to reassess the European aerospace champion's valuation. Analysis suggests the stock may be trading at a significant discount to its intrinsic value, even as it navigates production challenges and a robust order book.
The Texas-based financial institution reported a year-over-year increase in profits, deposits, and loans for the second quarter of 2025. While management highlighted the success of its organic branch expansion strategy, it also acknowledged intensifying competitive pressures in key lending markets.
Shares and bonds of New World Development surged after reports that Blackstone is in advanced talks to become its largest shareholder, a potential lifeline for the embattled Hong Kong property giant and a signal of shifting sentiment in the city's real estate market.
A new analysis reveals the stark reality of homeownership in California, where residents in its largest cities are spending a historically high share of income on housing, pushing the dream of owning a home out of reach for many.
Brookfield Infrastructure Partners capped a strong 2025 with double-digit FFO growth, a record capital recycling program, and a raised distribution. Management highlighted a massive, disciplined expansion in data infrastructure to meet AI-driven demand, forecasting a return to 10%+ growth targets.
